Ketamine-Prazosin Combined Pharmacotherapy in Post-Traumatic Stress Disorder and Alcohol Use Disorder: Targeting Complementary Neurobiological Mechanisms.
The Nursing clinics of North America – March 01, 2026
Source: PubMed
Summary
A compelling rationale exists for combining Ketamine and Prazosin to treat co-occurring Posttraumatic stress disorder (PTSD) and Alcohol use disorder (AUD). Ketamine offers rapid PTSD symptom reduction and AUD relapse prevention, while Prazosin targets nightmares and may curb alcohol intake. Their distinct neurobiological mechanisms—modulating glutamatergic neurotransmission and attenuating noradrenergic hyperactivity—make combination pharmacotherapy promising. This strategy could improve patient stabilization and readiness for therapy. Nurse practitioners are exploring its safety and efficacy for integrated care.
Abstract
Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD) often co-occur, worsening outcomes, relapse rates, and treatment response. Ketamine produces rapid and sustained PTSD symptom reduction and reduces AUD relapse. Prazosin effectively treats PTSD-related nightmares and may reduce alcohol consumption in individuals with heightened autonomic reactivity. The dual complementary mechanisms, modulation of glutamatergic neurotransmission and attenuation of noradrenergic hyperactivity, provide a compelling rationale for combination pharmacotherapy. Potential benefits include improved stabilization, readiness for trauma-focused therapy, and broader symptom control. Although untested in clinical trials, this approach warrants nurse practitioner-led research to evaluate safety, efficacy, and integration into multidisciplinary care.